Cretostimogene Grenadenorepvec is named as a drug or biological intervention in 3 clinical trials in our USA and China trial registers, 1 of which is recruiting. Lead sponsors include CG Oncology, Inc. (2) and Lepu Biopharma Co., Ltd. (1). Registered phases: Phase 3 and Phase 2. Conditions studied include Non Muscle Invasive Bladder Cancer; High-grade Ta/ T1 Papillary Disease Bladder Cancer; Urologic Cancer.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07283835 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (ClinicalTrials.gov ↗) Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer |
Phase 2 | Recruiting |
| NCT04452591 | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin (ClinicalTrials.gov ↗) Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer |
Phase 3 | Active, closed |
| NCT06111235 | A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT (ClinicalTrials.gov ↗) Non Muscle Invasive Bladder Cancer, Urologic Cancer, Bladder Cancer |
Phase 3 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Non Muscle Invasive Bladder Cancer | 3 |
| High-grade Ta/ T1 Papillary Disease Bladder Cancer | 2 |
| Urologic Cancer | 1 |
| Bladder Cancer | 1 |
| Urothelial Carcinoma | 1 |
| Lead sponsor | Trials |
|---|---|
| CG Oncology, Inc. | 2 |
| Lepu Biopharma Co., Ltd. | 1 |
| Register | Cretostimogene Grenadenorepvec trials |
|---|---|
| Clinical trials in USA | 2 |
| Clinical trials in China | 2 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cretostimogene Grenadenorepvec works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cretostimogene Grenadenorepvec (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.